Sunshine Lake Pharma (HKG:6887) began trading at HK$57.50 on the Hong Kong bourse on Thursday, following its listing by introduction, after completing a merger with Yichang HEC Changjiang Pharmaceutical (HKG:1558).
The vertically integrated drugmaker's listing involved no fundraising.
A total of 112.7 million Sunshine Lake H-shares were admitted to trading on the main board, issued to HEC shareholders at a share exchange ratio of 0.263614 Sunshine Lake share for each HEC H-share cancelled.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。